Medical Device User Fee Small Business Qualification and Certification 0910-0508 SUPPORTING STATEMENT

Terms of Clearance: None.

A. Justification

1. <u>Circumstances Making the Collection of Information Necessary</u>

Abstract

The Medical Device User Fee and Modernization Act of 2002 (MDUFMA) requires FDA to collect a user fee from each person who submits certain medical device applications for FDA review. See section 738(a)(1) and (a)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 379j(a)(1) and (a)(2)) http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapVII-partC-subpart3-sec379j.pdf. A "small business" is eligible for reduced or waived fees; small business fees for fiscal year (FY) 2016. If an applicant does not provide information to FDA demonstrating to FDA's satisfaction that the applicant is a small business, the applicant must pay the standard (full) fee for any application it submits.

Sections 738(d)(2)(A) and (e)(2)(A) define a "small business" as an entity that reported \$100 million or less of gross receipts or sales in its most recent Federal income tax return, including such returns of its affiliates, partners, and parent firms. If a firm's gross receipts or sales are no more than \$30 million (including all affiliates, partners, and parent firms), they will also qualify for a waiver of the fee for their first (ever) premarket application (PMA), product development protocol (PDP), biological licensing application (BLA), or premarket report.

Both Forms FDA 3602 and FDA 3602A are available in the guidance document, "FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments." http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm456779.pdf.

This guidance describes the criteria FDA will use to decide whether an entity qualifies as a MDUFMA small business and will help prospective applicants understand what they need to do to meet the small business criteria for FY 2016.

2. Purpose and Use of the Information Collection

FDA is the sole user of the information collected through Forms FDA 3602 and FDA 3602A. The forms will also serve to help entities understand the statutory requirements they must meet to qualify as a "small business."

FDA will use the information submitted on Forms FDA 3602 and FDA 3602A to decide whether the entity meets the requirements of section 738(d)(2)(A) and (e)(2)(A) of the FD&C Act. FDA's review of each form will ensure that the entity has identified all of its affiliates, partners, or parent firms, and that the total gross receipts and sales of the entity (including all affiliates, partners, or parent firms) is no more than \$100 million. If the entity qualifies as a "small business," FDA will inform the entity that it is eligible for reduced or waived fees for all medical device applications it submits to FDA during FY 2016.

The respondents to this information collection are private sector businesses or other forprofit entities.

3. <u>Use of Improved Information Technology and Burden Reduction</u>

Section 738(d)(2)(B) and (e)(2)(B) of the FD&C Act specifically requires an entity to submit "a copy of its most recent Federal income tax return … and a copy of such returns of its affiliates, partners, and parent firms" as evidence that it qualifies as a MDUFMA small business. At this time, FDA does not collect the information electronically. However, we are considering the feasibility of collecting the information by electronic means in the future.

4. Efforts to Identify Duplication and Use of Similar Information

Forms FDA 3602 and FDA 3602A do not duplicate any other information collection.

5. <u>Impact on Small Businesses or Other Small Entities</u>

Forms FDA 3602 and FDA 3602A collect the minimum information FDA requires to efficiently and quickly determine whether an entity is a small business. Most of the respondents are businesses. Section 738(d)(2)(B) and (e)(2)(B) of the FD&C Act specifies the evidence that an entity must submit to qualify for small business fees or waivers. The information collection has been held to the absolute minimum required for the intended use of the data. Approximately 90% of entities that submit an application qualify as a MDUFMA small business. This estimate is based on the number of applications received in the last 3 years that were qualified a small business compared to entities that did not meet the criteria as a MDUFMA small business.

6. Consequences of Collecting the Information Less Frequently

Respondents will respond to this information collection occasionally.

MDUFMA requires FDA to collect a user fee from each person who submits certain medical device applications for FDA review (see section 738(a)(1) and (c)(5) of the FD&C Act). A "small business" is eligible for reduced or waived fees. This information collection allows FDA to determine whether an entity is a small business under section 738(d)(2)(A) and (e)(2)(A) of the FD&C Act. Only applicants that would like to be

considered a small business will respond to the collection. If an applicant does not provide the information to FDA, the applicant must pay the standard (full) fee for any application is submits. There are no legal obstacles to reduce the burden.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances for this collection of information.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

In accordance with 5 CFR 1320.8(d), FDA published a 60-day notice for public comment in the FEDERAL REGISTER of September 17, 2015 (80 FR 55854). Although one comment was received, it was not responsive to the four collection of information topics solicited and therefore will not be discussed in this document.

9. Explanation of Any Payment or Gift to Respondents

This information collection does not provide for payment or gifts to respondents.

10. Assurance of Confidentiality Provided to Respondents

Information that is trade secret or confidential commercial information is subject to FDA's regulations on the release of information, 21 CFR Part 20.

11. <u>Justification for Sensitive Questions</u>

This information collection does not involve any questions of a sensitive nature.

12. Estimates of Annualized Burden Hours and Costs

12a. Annualized Hour Burden Estimate

FDA estimates the burden of this collection of information as follows:

Table 1.--Estimated Annual Reporting Burden

FDA Form No.	No. of	No. of Responses	Total Annual	Average	Total
	Respondents	per Respondent	Responses	Burden per	Hours
	-	1	-	Response	
FDA 3602FY 2016	3,600	1	3,600	1	3,600
MDUFA Small Business					
Qualification and					
Certification For a Business					
Headquartered in the United					
States					
FDA 3602A FY 2016	1,400	1	1,400	1	1,400
MDUFA Foreign Small					
Business Qualification and					
Certification For a Business					
Headquartered Outside the					
United States					
Total					5,000

This burden is based on the number of applications received in the last 3 years and includes time required to collect the required information. Based on our experience with Form FDA 3602, FDA believes it will take each respondent 1 hour to complete the form.

Based on our experience with Form FDA 3602A, FDA believes that it will take each respondent 1 hour to complete.

12b. Annualized Cost Burden Estimate

The annualized cost burden estimate includes the salaries for personnel who prepare the forms. We expect that approximately half of the hour burden will be work performed by an Accountant and approximately half by a Regulatory Affairs Professional. The annualized cost burden estimate is based on the mean hourly wage rate for an Accountant, \$35.42,* and the estimated hourly wage rate for a Regulatory Affairs Professional, \$30.85.**

^{**}The estimated hourly wage rate for a Regulatory Affairs Professional is based on the annual median salary, \$64,159, listed on PayScale.com, http://www.payscale.com/research/US/Job=Regulatory_Affairs_Specialist/Salary (as of February 2016). The hourly rate assumes a 40-hour work week and has been rounded to the nearest dollar.

Type of Respondent	Total Burden Hours	Hourly Wage Rate	Total Respondent Costs
Accountants	2,550	\$35.42	\$90,321
Regulatory Affairs	2,550	\$30.85	\$78,668
Total			\$168,989

13. Estimates of Other Total Annual Costs to Respondents and/or Recordkeepers/Capital Costs

^{*}May 2014 Bureau of Labor and Statistics data, occupation code 13-2011 Accountants and Auditors, http://www.bls.gov/oes/current/oes nat.htm#13-0000.

There are no capital costs or operating and maintenance costs associated with this collection of information.

14. Annualized Cost to the Federal Government

FDA will review each Form FDA 3602 and FDA 3602A and each accompanying Federal income tax return to confirm the accuracy of information provided for an entity and to ensure that the entity qualifies as a "small business" within the meaning of MDUFMA. As part of its review, FDA will review commercial databases to determine whether the entity has any affiliates, partners, or parent firms that it did not identify on the FDA Forms 3602 and 3602A. FDA believes it will have to expend approximately 1 hour of effort on each FDA Form 3602 and 3602A. We doubled the hourly rate for a GS-13 employee (\$57.40)* to account for overhead (total, \$115 per hour). With 5,000 submissions to be reviewed, FDA estimates that the total cost to the Federal government will be \$575,000.

*U.S. Office of Personnel Management, Salary Table 2016-DCB, GS-13, step 10 (https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/salary-tables/16Tables/html/DCB h.aspx)

15. Explanation for Program Changes or Adjustments

The total reporting burden hours have been adjusted due to an updated number of respondents participating in the program. This resulted in a decrease of 100 hours in the overall burden estimate.

16. Plans for Tabulation and Publication and Project Time Schedule

Not applicable.

17. Reason(s) Display of OMB Expiration Date is Inappropriate

FDA is not seeking an exemption to display the expiration date.

18. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification.